Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.

@article{Guo2006MineralocorticoidRA,
  title={Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.},
  author={Christine Z Guo and Diego Martinez-Vasquez and Gonzalo P. M{\'e}ndez and Maria F Toniolo and Tham M. Yao and Eveline M Oestreicher and Taisuke Kikuchi and Nathalie Lapointe and Luminita Pojoga and Gordon H. Williams and Vincent Ricchiuti and Gail K. Adler},
  journal={Endocrinology},
  year={2006},
  volume={147 11},
  pages={5363-73}
}
To determine whether mineralocorticoid receptor (MR) activation plays a role in diabetic renal injury and whether this role differs in types 1 and 2 diabetes mellitus, we examined the effect of a MR antagonist on renal injury in rodent models of type 1 (streptozotocin-treated rat) and type 2 (db/db mouse) diabetes. We studied three groups of 8-wk-old, uninephrectomized Wistar rats for 4 wk: diabetic streptozotocin- (55 mg/kg) treated rats (n = 11), diabetic streptozotocin-treated rats receiving… CONTINUE READING